Pharmacological treatment of cardiogenic shock - A state of the art review

Pharmacol Ther. 2022 Dec:240:108230. doi: 10.1016/j.pharmthera.2022.108230. Epub 2022 Jun 10.

Abstract

Cardiogenic shock is a clinical syndrome of impaired tissue perfusion caused by primary cardiac dysfunction and inadequate cardiac output. It represents one of the most lethal clinical conditions in intensive care medicine with mortality >40%. Management of different clinical presentations of cardiogenic shock includes guidance of cardiac preload, afterload, heart rate and contractility by differential pharmacological modulation of volume, systemic and pulmonary vascular resistance and cardiac output besides reversing the triggering cause. Data from large registries and randomized controlled trials on optimal diagnostic guidance as well as choice of pharmacological agents has accrued significantly in recent years. This state-of-the-art review summarizes the basic concepts of cardiogenic shock, the diagnostic work-up and currently available evidence and guideline recommendations on pharmacological treatment of cardiogenic shock.

Keywords: Cardiogenic shock; Heart failure; Pharmacological treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Heart
  • Heart Diseases*
  • Humans
  • Shock, Cardiogenic* / diagnosis
  • Shock, Cardiogenic* / drug therapy
  • Shock, Cardiogenic* / etiology